300 related articles for article (PubMed ID: 15301561)
41. Infliximab therapy for pediatric Crohn's disease.
Veres G; Baldassano RN; Mamula P
Expert Opin Biol Ther; 2007 Dec; 7(12):1869-80. PubMed ID: 18034652
[TBL] [Abstract][Full Text] [Related]
42. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions.
Lecluse LL; Piskin G; Mekkes JR; Bos JD; de Rie MA
Br J Dermatol; 2008 Sep; 159(3):527-36. PubMed ID: 18627374
[TBL] [Abstract][Full Text] [Related]
43. Acute coronary syndrome after infliximab therapy in a patient with Crohn's disease.
Panteris V; Perdiou A; Tsirimpis V; Karamanolis DG
World J Gastroenterol; 2006 Oct; 12(38):6235-8. PubMed ID: 17036404
[TBL] [Abstract][Full Text] [Related]
44. Psoriasis induced by infliximab in a patient suffering from Crohn's disease.
Manni E; Barachini P
Int J Immunopathol Pharmacol; 2009; 22(3):841-4. PubMed ID: 19822070
[TBL] [Abstract][Full Text] [Related]
45. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
Suhler EB; Smith JR; Wertheim MS; Lauer AK; Kurz DE; Pickard TD; Rosenbaum JT
Arch Ophthalmol; 2005 Jul; 123(7):903-12. PubMed ID: 16009830
[TBL] [Abstract][Full Text] [Related]
46. A lupus-like syndrome associated with infliximab therapy.
Klapman JB; Ene-Stroescu D; Becker MA; Hanauer SB
Inflamm Bowel Dis; 2003 May; 9(3):176-8. PubMed ID: 12792223
[TBL] [Abstract][Full Text] [Related]
47. Mechanisms in failure of infliximab for Crohn's disease.
Nikolaus S; Raedler A; Kühbacker T; Sfikas N; Fölsch UR; Schreiber S
Lancet; 2000 Oct; 356(9240):1475-9. PubMed ID: 11081530
[TBL] [Abstract][Full Text] [Related]
48. Demyelination-like syndrome in Crohn's disease after infliximab therapy.
Freeman HJ; Flak B
Can J Gastroenterol; 2005 May; 19(5):313-6. PubMed ID: 15915246
[TBL] [Abstract][Full Text] [Related]
49. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
Sandborn WJ; Hanauer S; Loftus EV; Tremaine WJ; Kane S; Cohen R; Hanson K; Johnson T; Schmitt D; Jeche R
Am J Gastroenterol; 2004 Oct; 99(10):1984-9. PubMed ID: 15447761
[TBL] [Abstract][Full Text] [Related]
50. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.
Hanauer SB; Wagner CL; Bala M; Mayer L; Travers S; Diamond RH; Olson A; Bao W; Rutgeerts P
Clin Gastroenterol Hepatol; 2004 Jul; 2(7):542-53. PubMed ID: 15224278
[TBL] [Abstract][Full Text] [Related]
51. [Anti-TNF (infliximab) treatment in Crohn disease: safety profile].
Carroccio A; Di Prima L; Pirrone G; Ambrosiano G; Noto D; Cefalù AB
Recenti Prog Med; 2006 Feb; 97(2):108-12; quiz 122. PubMed ID: 16671277
[TBL] [Abstract][Full Text] [Related]
52. Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical experience.
Vultaggio A; Matucci A; Parronchi P; Rossi O; Palandri F; Romagnani S; Maggi E
Int J Immunopathol Pharmacol; 2008; 21(2):367-74. PubMed ID: 18547481
[TBL] [Abstract][Full Text] [Related]
53. Strategies for targeting tumour necrosis factor in IBD.
Sandborn WJ
Best Pract Res Clin Gastroenterol; 2003 Feb; 17(1):105-17. PubMed ID: 12617886
[TBL] [Abstract][Full Text] [Related]
54. Anti-tumor necrosis factor-α induced systemic lupus erythematosus in a patient with metastatic Crohn's disease--what is the role of anti-TNF antibody?
Farkas K; Nagy F; Kovács L; Wittmann T; Molnár T
J Crohns Colitis; 2013 May; 7(4):e143-5. PubMed ID: 22818164
[TBL] [Abstract][Full Text] [Related]
55. Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study.
Babouri A; Roblin X; Filippi J; Hébuterne X; Bigard MA; Peyrin-Biroulet L
J Crohns Colitis; 2014 Feb; 8(2):161-5. PubMed ID: 23994253
[TBL] [Abstract][Full Text] [Related]
56. Infliximab therapy in children and adolescents with inflammatory bowel disease.
Veres G; Baldassano RN; Mamula P
Drugs; 2007; 67(12):1703-23. PubMed ID: 17683171
[TBL] [Abstract][Full Text] [Related]
57. Infliximab treatment of rheumatoid arthritis and Crohn's disease.
Nahar IK; Shojania K; Marra CA; Alamgir AH; Anis AH
Ann Pharmacother; 2003 Sep; 37(9):1256-65. PubMed ID: 12921510
[TBL] [Abstract][Full Text] [Related]
58. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction.
Kugathasan S; Levy MB; Saeian K; Vasilopoulos S; Kim JP; Prajapati D; Emmons J; Martinez A; Kelly KJ; Binion DG
Am J Gastroenterol; 2002 Jun; 97(6):1408-14. PubMed ID: 12094858
[TBL] [Abstract][Full Text] [Related]
59. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus.
Aringer M; Steiner G; Graninger WB; Höfler E; Steiner CW; Smolen JS
Arthritis Rheum; 2007 Jan; 56(1):274-9. PubMed ID: 17195231
[TBL] [Abstract][Full Text] [Related]
60. Maintenance infliximab therapy in patients with Crohn's disease: how long, how much, how frequent?
Cuffari C; Lichtenstein GR
Gastroenterology; 2003 Jun; 124(7):1988-90. PubMed ID: 12806638
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
